Tango Therapeutics (TNGX) 44th Annual J.P. Morgan Healthcare Conference summary

Leadership and Strategic Direction

• Malte Peters, MD, appointed CEO, brings extensive late-stage development and regulatory experience from roles at MorphoSys, Sandoz, and Novartis Oncology, ensuring continuity as he has been involved since 2018.

• Leadership transition aligns with the shift from early development to late-phase drug development and regulatory focus, with Peters aiming to translate clinical achievements into value for patients and shareholders.

• Peters' familiarity with the board, executive team, and ongoing projects ensures a smooth transition, with no major strategic changes expected.

• Leadership aims to drive the next phase of growth with a focus on innovative combination regimens.

Market Opportunity and Scientific Rationale

• MTAP deletion is a common genetic alteration in several cancers, affecting 60,000 patients annually in the US, with high prevalence in pancreatic, lung, and glioblastoma.

• MTAP deletion confers sensitivity to PRMT5 inhibitors, creating a large development opportunity.

Pipeline Highlights and Clinical Progress

• Pipeline targets MTAP-deleted cancers with PRMT5 inhibitors: TNG462 (vopimetostat) in dose expansion and combination studies, TNG908 for brain-penetrant activity, and TNG961 ready for clinical trials.

• TNG462/vopimetostat shows 27% response rate and 6.4 months median progression-free survival in monotherapy, with strong tolerability; in 2L pancreatic cancer, 25% ORR and 7.2-month mPFS, outperforming historical SOC.

• In a histology-selective cohort, vopimetostat achieved a 49% ORR and 9.1-month mPFS, again outperforming historical controls.

• Combination studies with Revolution Medicines' RAS inhibitors show promising preclinical and early clinical activity, with 30 patients dosed and good tolerability, supporting a shift to chemo-sparing regimens.

• TNG908 phase 1/2 trial initiated for glioblastoma, with FDA Fast Track and Orphan Drug designations; TNG961 completed IND-enabling studies for FOCAD/MTAP-deleted cancers.